Current Status of Stereotactic Ablative Radiotherapy (SABR) for Early-stage Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2016.06.18
- VernacularTitle:早期非小细胞肺癌立体定向消融放疗现状
- Author:
SHI ANHUI
1
;
ZHU GUANGYING
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所放射治疗科
- Keywords:
Lobectomy;
Video-assisted thoracoscopic surgery;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2016;19(6):389-393
- CountryChina
- Language:Chinese
-
Abstract:
High level evidence from randomized studies comparing stereotactic ablative radiotherapy (SABR) to surgery is lacking. Although the results of pooled analysis of two randomized trials for STARS and ROSEL showed that SABR is better tolerated and might lead to better overall survival than surgery for operable clinical stage I non-small cell lung cancer (NSCLC), SABR, however, is only recommended as a preferred treatment option for early stage NSCLC patients who cannot or will not undergo surgery. We, therefore, are waiting for the results of the ongoing randomized studies [Veterans af-fairs lung cancer surgery or stereotactic radiotherapy in the US (VALOR) and the SABRTooth study in the United Kingdom (SABRTooths)]. Many retrospective and case control studies showed that SABR is safe and effective (local control rate higher than 90%, 5 years survival rate reached 70%), but there are considerable variations in the deifnitions and staging of lung cancer, operability determination, and surgical approaches to operable lung cancer (open vs video-assisted). hTerefore, it is diffcult to compare the superiority of radiotherapy and surgery in the treatment of early staged lung cancer. Most studies demonstrated that the effcacy of the two modalities for early staged lung cancer is equivalent;however, due to the limited data, the conclu-sions from those studies are diffcult to be evidence based. hTerefore, the controversies will be focusing on the safety and inva-siveness of the two treatment modalities. hTis article will review the ongoing debate in light of these goals.
